Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Study on Therapy With the NF-κB Inhibiting and Apoptosis Inducing Drug Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)

NCT02546440 is registered in ClinicalTrials.gov with Universitätsmedizin Mannheim as lead sponsor.

NCT NCT02546440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02546440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Study on Therapy With the NF-κB Inhibiting and Apoptosis Inducing Drug Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
Lead sponsor
Universitätsmedizin Mannheim
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
September 30, 2022
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t cell lymphoma